METHOD FOR PREDICTING CANCER RESPONSE TO IMMUNOTHERAPY TREATMENT WITH ANTI-PD1
Description
Cancer is one of the most studied diseases in recent years, due to its high incidence and mortality. The use of immune control inhibitors, ICBs, has revolutionized cancer treatment, as acceptable toxicity and long-lasting response have been demonstrated in responders. The use of the programmed death ligand inhibitor (anti-PD1) is a common treatment in patients with advanced melanomas, which has been shown to have a 20% higher response rate than with chemotherapy and with better tolerability. However, a percentage of patients are insensitive or develop resistance, so it is necessary to have a pattern of predictive biomarkers that allows deciding whether or not to use anti-PD1. In this invention, a molecular biomarker profile is identified, which allows patients to be classified according to their response profile, based on gene expression variations.
Advantages
This invention has the following advantages: - It allows to determine in advance if the anti-PD1 treatment is suitable for the patient. - It reduces the economic costs and the adverse effects associated with the use of non-responsive treatments for certain patients.
Uses and Applications
Invention belonging to the Biotech-Pharma sector. Specifically, the prognosis of treatment in oncology.
Keywords
Sectors
Areas
Patent Number
EP4069869A0 Expediente
Applicants
Universidad De Málaga, Junta De Andalucía. Consejería De Salud. Servicio Andaluz De Salud.
Inventors
Mª. Isabel Barragán Mallofret, Martina Alvarez Perez, Miguel Ángel Berciano Guerrero, Manuel Cobo Dols, Alicia Garrido Aranda, Alfonso Sánchez Muñoz, Francisco Javier Oliver Martos, Pedro Jiménez Gallego, Emilio Alba Conejo
Filing Date
04/12/2019
Protection Level: International
Processing Status: International protection application
